Mount Sinai Innovation Partners – Change in Leadership
TO: All Faculty, Staff, and Students
Kenneth L. Davis, MD - President and Chief Executive Officer, The Mount Sinai Medical Center
Dennis S. Charney, MD - Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, Executive Vice President for Academic Affairs, The Mount Sinai Medical Center
Scott L. Friedman, MD - Dean for Therapeutic Discovery, Icahn School of Medicine at Mount Sinai, Fishberg Professor of Medicine and Chief, Division of Liver Diseases, The Mount Sinai Medical Center
DATE: August 14, 2013
RE: Mount Sinai Innovation Partners — Change in Leadership
Following the successful reorganization of Mount Sinai’s technology transfer program from the Office of Technology & Business Development to Mount Sinai Innovation Partners (MSIP), our Vice President of Technology and Business Development, Teri Willey, will be leaving Mount Sinai the end of August to lead technology transfer at Cold Spring Harbor Laboratories.
Please join us in thanking Teri for her superb leadership in expanding MSIP, ably serving the needs of our faculty, and bringing a new vitality to technology transfer throughout the institution. Her successful efforts in aligning her team’s mission with Mount Sinai’s innovation agenda have positioned us well to seek a successor who can build upon her many achievements, and a search is actively under way. She leaves behind a strong, expanded senior team who will manage the day-to-day work of MSIP under the interim leadership of Scott L. Friedman, MD, in his role as Dean for Therapeutic Discovery.
Last year, MSIP worked with 325 faculty, staff, students, and trainees in exploring commercial partnering options for research projects being performed in our laboratories. Six hundred ninety-five material transfer, confidential disclosure, and inter-institutional agreements were signed last year, and a record $76 million in revenues were generated by licenses and options.
MSIP’s activities include evaluating, patenting, marketing, and licensing new technologies, and negotiating agreements for sponsored research, material transfer, and confidentiality. Blue Mountain Technologies is an MSIP program that enhances the distribution and product development of Mount Sinai’s growing portfolio of novel reagents, diagnostics, and therapeutics.
For more about the MSIP team and related information, please visit http://ip.mountsinai.org.